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There have been many exciting new breakthroughs in understanding tumour biology. This has opened up the possibility of per-
sonalized treatment for people with certain tumours. The epidermal growth factor receptor (EGFR) and K-ras are two such targets
thatcanhelpclassifytumoursonamolecularbasisandguidetreatmentdecisions.However,therearestillquestionsabouthowbest
to implement new molecular tests like these to characterize tumours in clinical practice. Potential obstacles include availability of
good quality tissue specimens, access to the right test, and consensus about interpretation, funding, and availability. In this paper,
we review these issues, by discussing these two examples in detail and suggest some actions for addressing potential barriers.
1.Introduction
The landscape of treatment options in medical oncology
is changing rapidly. Apart from traditional cytotoxic med-
ications, there are now increasing numbers of targeted bi-
ological agents and immunotherapy treatments. We are
developing better insights into the molecular biology of neo-
plastic disease and the pharmacology/pharmacodynamic of
cytotoxics and novel biologic agents. However, there are vast
areas of uncertainties about eﬃcacy and toxicity prediction
of various treatments. There are multiple factors related to
thetumourandthepatientthatplaycrucialroledetermining
these properties. Molecular testing of tumours is a ﬁeld that
is starting to shed light on this area and permits us to make
more individualised treatment decisions, including choosing
the right drug for the right patient.
There are many speciﬁc molecular tests that are already
in routine clinical use such as testing HER-2 in breast can-
cer, bcr-abl in CML, and c-Kit in gastrointestinal stromal
tumours. There are other tests which have suﬃcient evidence
for clinical utility but are not yet widely available or govern-
ment funded. Here we explore the issues that lead to delay in
routine implementation of these kinds of tests by discussing
the examples of K-ras mutation testing in colon cancer and
EGFR mutation testing in lung cancer.
2. K-ras
Cetuximab and panitumumab are anti-EGFR monoclonal
antibodies that are usually considered in the 2nd to 3rd line
treatment setting for metastatic colorectal cancer and in
selected patients for ﬁrst-line therapy where downstaging
prior to curative metastasectomy is being considered. There
are downstream components from EGFR that can determine
the eﬃcacy of this strategy. K-ras, short for Kirsten ras, is
one such downstream G protein. Its mutation can confer
stimulus-independent activation of the pathway. The preva-
lence of the mutation in colorectal cancer is 30–60% and the
mutation status in the primary tumour and metastasis from
the same individual is reported to be highly concordant [1–
5].
The presence of a K-ras mutation in a tumour is now
widelyacceptedasanegativepredictivefactorforresponseto
anti-EGFR antibody treatment. Several studies have shown
lack of any beneﬁt or actual detriment from anti-EGFR
antibody treatment in colorectal cancer patients if K-ras
is mutated [6–13]. For example, as a single agent in the
settingofadvancedcolorectalcancer,Cetuximabresultsinan
improvementinmediansurvivalofaround4.7months(near
doubling) compared to placebo in patients with K-ras wild-
type (WT) tumours but no statistically signiﬁcant diﬀerence2 Chemotherapy Research and Practice
in patients with K-ras mutant tumours [6]. In quantitative
terms, 0.39 life years (LY) and 0.25 quality adjusted life years
(QALY) are gained.
In several countries Cetuximab treatment is government
funded only for patients with K-ras wild-type colorectal
cancer, in whom it has been determined to be cost-eﬀective
treatment.HencetestingforthepresenceofaK-rasmutation
is considered a codependent technology. However the testing
is not currently funded by public or private payers in many
places such as Australia. It can be accessed by a patient self-
fundingthetest,thepharmaceuticalcompany’sspecialaccess
program or as part of a clinical trial. Various questions about
testing that have been obstacles to government funding of
testing and potential answers are discussed below.
2.1. When to Test? A K-ras mutation test can potentially be
requested at diﬀerent time points in the natural history of
colorectal cancer. This could be at (a) initial diagnosis of
colorectal cancer, (b) at diagnosis of metastasis, or (c) at
failure of 1st-line treatment for metastatic disease.
The decision requires consideration of cost, turnaround
time, and diﬃculties in retrieval of adequate tissue for test-
ing. Option (a) is the simplest but the most costly. It allows
adequate good quality tissue to be available for most of the
patients. However, a large number of patients with locally
advanced CRC will not progress to metastatic disease and
hence the result of K-ras testing wouldn not be needed as it
is not in itself a prognostic marker. Option (c) is the cheapest
as it would test only those patients who need the result.
However, it falls down due to potential time lost in retrieval
and testing of a specimen when the window of opportunity
for treatment may be short.
Option(b)isafaircompromisebetweenthetwoasitwill
allowtheresulttobeavailableinatimelymannerforpatients
before a decision needs to be made about second-line treat-
ment for most patients. Nevertheless it may still result in
small numbers of patients being tested who die before 2nd-
line treatment can be initiated or may be cured by ﬁrst line
therapy including surgery for oligometastatic disease.
2.2. What to Test? In some settings the presence of somatic
mutations in tumours can vary between the primary and
metastases. Fortunately, the K-ras mutation status is thought
to be stable between a colorectal tumour primary and
metastaticdeposit,withthecorrelationbetweenprimaryand
metastases reported to be 93% (range 76–100%) [14–16].
This means that the test can usually be done on the primary
resection specimen, even though the result is used for the
treatment of metastatic disease which may not develop until
some years down the track. However, if enough good quality
tissue is not available, then biopsy of a site of metastatic
disease may be required.
There are several sources of false-positive and false-
negative results for K-ras testing of tumour samples, with
obvious ﬂow on eﬀects including the denial of a useful treat-
ment or use of inappropriate therapy, respectively. For exam-
ple, formalin ﬁxed paraﬃn embedded (FFPE) specimens
can have artiﬁcial mutations induced during the processing
resulting in reduced speciﬁcity. However, if there is enough
cancer cells in a specimen than this random error can be
avoided. Reactive cells in the tissue stroma and neighbouring
normal cells can also compete for DNA ampliﬁcation with
cancercellsandcanreducesensitivityofthetest[17].Macro-
or micro-dissection or taking a selective needle core from a
tissue block are ways to enrich the specimen to be tested for
tumour. Care must be taken to obtain enough tumour tissue
to have enough DNA for testing. At least 300 cancer cells or
30ng of DNA is reported to optimize yield [18].
2.3. How to Test? There are a multitude of available methods
to detect K-ras mutations. International recommendations
are that a sensitive, speciﬁc, and reliable DNA-based assay
be used [19]. The common methods are direct sequencing,
RFLP (Restriction Fragmentation Length Polymorphism),
ASO(AlleleSpeciﬁcOligonucleotide)Hybridization,HRMA
(High Resolution Melting Analysis), ARMS (Ampliﬁcation
Refractory Mutation System), and pyrosequencing. There is
no common test that has been used across multiple clinical
trials. There are drawbacks for all methods with limitations
in sensitivity, speciﬁcity, or practicability due to cost or
turnaround time [17]. Nevertheless, there is still reasonable
concordancebetweenresultsbythediﬀerenttestingmethods
[20].
Direct sequencing is considered the gold standard as it
is able to detect all mutations in the K-ras gene but also
hassomedrawbacks.Forexample,directsequencingrequires
a minimum 20% mutation load (mutant cells/total cells)
to be positive. Some nonmutant tumours (as per direct
sequencing) turned out to harbour mutant cells when exam-
ined with the more sensitive pyrosequencing method [21].
In another study, direct sequencing was compared directly
with mutation-enriched sequencing in 90 colorectal carci-
nomas. K-ras mutations were detected in 40% by means of
direct sequencing and 55% by means of mutation-enriched
sequencing. Hence minor clones were detected in about 15%
of colorectal cancers [22].
The essential requirement is that the testing is validated
and performed in an accredited laboratory with an external
quality assurance program. The availability of the test is not
widespread so this may require transport of appropriate tis-
sue, once it is identiﬁed and retrieved from storage, from the
original laboratory to another laboratory. This adds further
delay in getting results. It is helpful when requesting tissue
from the source laboratory to indicate how urgent or not the
request is for patient care.
2.4. How to Interpret the Result of Testing? Generally if a K-
ras mutation is detected then a patient will not be considered
appropriate for anti-EGFR antibody treatment. The use of
highly sensitive detection methods will in more mutations
be identiﬁed [23]. However, the threshold mutation load
w i t h i naK - r a sm u t a n tt u m o u rs p e c i m e ni sn o tw e l ld e ﬁ n e d ;
beyondwhichthereisdeﬁnitefutilityoftheuseofanti-EGFR
antibodies in patients. For example, treatment response has
been described in tumours which harbour only a small per-
centage of mutated cells (<20%) [21]. Hence caution hasChemotherapy Research and Practice 3
been recommended in the interpretation of the use of
very sensitive testing methods such as pyrosequencing. The
thresholdusedintherelevantclinicaltrialshasunfortunately
not been consistently reported as outlined in Table 1 [6].
The known mutations are few. Ninety percent involve
3 codons (Exon 2: codon 12–79%, codon 13–17.6%, and
Exon 3: codon 61–1%) [17]. It is not yet clear if the biology
of diﬀerent mutations is similar. There are suggestions that
certain mutations (e.g., G13D) do not confer resistance to
Cetuximab, though these observations need to be conﬁrmed
by prospective trials and were not replicated in analysis
of a recent panitumumab trial [26, 27]. Currently, it is
not routine to diﬀerentiate speciﬁc mutations for clinical
decision making.
2.5. Is Testing Suﬃcient to Predict Response? K-ras wild-type
status is necessary but not suﬃcient to predict response
to treatment. Although it is clear that the vast majority of
patients with a K-ras mutant tumour will not respond to
treatment, nearly 60% of patients will also not have a re-
sponse to anti-EGFR antibody treatment despite having a
K-ras WT tumour. Other potential predictive markers have
also been post hoc or retrospectively identiﬁed such as EGFR
gene copy number, mRNA expression for the EGFR ligands,
epiregulin and amphiregulin, and wild-type BRAF [11, 28,
29]. There will most likely be others identiﬁed with time;
howeverinallcasesconﬁrmationisrequiredinwell-designed
prospective trials.
2.6. Is Testing Cost-Eﬀective? It is established that use of anti-
EGFR antibodies such as cetuximab is only cost-eﬀective if
used for the treatment of patients with WT K-ras tumours
[30]. Most of the pivotal clinical trials have focussed on
eﬃcacy and safety and some have not included prospective
economic evaluation of the therapeutic intervention. Previ-
ously it has not been routine to include economic analysis of
codependent diagnostic tests in clinical trials. However this
is needed before policy makers allocate funds for testing in
routine clinical practice.
Determining the true cost of testing is not straightfor-
ward. Whether you include only direct costs (salary for staﬀ,
reagents, and equipment) or indirect costs as well (tissue
retrieval from another institution) generates a substantial
diﬀerence in costing. One economic modelling proposed by
Merck Sorano to the Australian Pharmaceutical Beneﬁts
Advisory Committee showed a cost of AU$45000–75000 for
use of Cetuximab, including K-ras testing, per QALY gained.
This was considered high but still reasonable and eventually
resulting in the government approving the funding of
Cetuximab. The presumed cost of the test itself in the model
made up only a very small component of the cost at AUD
250 and is suggested to be cost-eﬀective based on recent
modelling from a Swiss group [31]. However, currently the
test is not funded by the Australian government as it has yet
to get through the approval pathway for codiagnostic testing
which has historically been a separate and disjointed process
from the drug approval pathway. The regulatory authorities
are now attempting to streamline the process by concurrent
evaluation of the diagnostic tests with drug approval.
3.EGFR
EGFR tyrosine kinase inhibitors (TKIs) are known to result
in dramatic responses and prolonged survival times for
patients with EGFR mutant non-small-cell lung cancer
(NSCLC). They are used in the 1st- to 3rd-line treatment
setting in patients with EGFR activating mutations as well
as maintenance treatment after ﬁrst-line chemotherapy. It
has been recently established that EGFR testing is essential
before giving an EGFR TKI in the ﬁrst-line setting as there
is negative impact of giving an EGFR TKI rather than
chemotherapy to a patient who is EGFR mutation negative
[32]. Studies have found that approximately 10% to 20% of
NSCLC tumours harbour somatic mutations in the EGFR
gene [33, 34].
In Australia treatment with Geﬁtinib is funded for the
treatment of relapsed NSCLC after chemotherapy, but only
for EGFR mutant patients. Erlotinib is also available for the
treatment of patients who relapse after chemotherapy, but
its use is not restricted by EGFR status because of the BR21
trial which demonstrated beneﬁt from use in this setting
in patients who were not prospectively tested for mutations
[35]. First-line treatment is not currently funded.
Also, testing for EGFR mutations is not currently gov-
ernment funded although like K-RAS testing it is consid-
ered a codependent technology for ﬁrst-line treatment. It
is available either as part of various clinical trials, in house
funding by some public hospitals, an access program run
by a pharmaceutical company, or the patient paying out-of-
pocket for the test.
3.1. When to Test? The test result is relevant for any patient
andtheirdoctorconsideringtreatmentofmetastaticNSCLC.
The chances of ﬁnding an EGFR mutation are signiﬁcantly
higher in patients who are never or light smokers, or those
who have nonsquamous histology [36, 37]. Hence it is
proposed that all such patients should have testing for EGFR
mutations. Patient who continue to smoke do not appear to
beneﬁt from treatment with an EGFR TKI due to eﬀects on
drug metabolism; therefore testing may not be of relevance
unless the patient is willing to try to stop smoking [38].
Given that a test result may take many weeks to obtain, it
is also sensible to test patients at diagnosis if they have locally
advanceddiseasewhichmaybepotentiallycurablebutwhere
the chance of relapse is high, for example, stage III disease. It
has also been suggested that there could be a time and cost
savingbyhavingtheoriginal reportingpathologistarranging
for the test to be performed while actively reporting the case
rather than having it retrieved for testing later.
One suggestion for selecting an enriched subset to test
is to use epidemiologic factors. The typical epidemiologic
factors associated with higher rates of EGFR mutation are
adenocarcinoma histology, female sex, never-smoker status,
and eastern Asian ethnicity. But using these features to
narrow down the patient subgroup for testing can miss some
patients as the mutation has been found, though in lower4 Chemotherapy Research and Practice
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frequency, in other subsets too (smokers, men, and other
ethnicities) [39]. It has been suggested that 31% of all
EGFR mutations would be missed if testing was restricted
to women, 40% would be missed if testing was restricted
to never smokers, and 57% would be missed if testing
was restricted to women who never smoked cigarettes. The
mutation is very rare in squamous histology (0–1.1%) and
hence the utility of testing these patients is low [40, 41].
3.2. What to Test? Testing for EGFR mutation status is usual-
lyperformedonthe primaryspecimenthatledtoadiagnosis
ofnon-small-celllungcancerasthismaybetheonlyavailable
tissue. This is a reasonable and practical approach. However,
there are reports suggesting potential discordance between
the primary tumour and metastases regarding EGFR status
[42]. Tumour progression and treatment can potentially
change the mutation status and create discrepancy between
theprimaryandmetastasis.Hencetreatmentdecisionsbased
purely on histology from the primary tumour can be mis-
leading when the focus of treatment is on metastasis. Even
withinsametumourtheremaybequitealotofheterogeneity
i nt e r m so ft h ep r e s e n c ea n dt y p eo fm u t a t i o n[ 43].
Nowadays, due to reliance on minimally invasive tech-
niques for diagnosis such as transbronchial or image-guided
percutaneous needle biopsies, sometimes available diagnos-
tic material may be limited. Generally a core biopsy at a
minimum is required for EGFR testing. Hence having cytol-
ogy alone for diagnosis is not currently recommended al-
though ways to test for mutations in cytological specimens
and/or blood are being investigated. Poor quality tissue with
low tumour/surrounding tissue ratio (<20%) can lead to
false-negative mutation testing results. To avoid this proper
planning for biopsy is needed. Sometimes PET guidance to
help target the best tissue for biopsy may be useful.
3.3. How to Test? The ﬁnding that is most convincingly asso-
ciated with response to EGFR TKI treatment is the presence
of an EGFR mutation in NSCLC. Some studies also report
a correlation between treatment responses and positive
immunohistochemistry or FISH testing for EGFR expres-
sion. However this association is much less robust and not
found in all studies and hence not recommended as a way to
select patients for treatment.
An u m b e ro fd i ﬀerent methods for detection of an EGFR
mutation can be used such as DNA sequencing, HRMA, or
ARMS. There is no single agreed-upon method; however
direct sequencing is currently considered the gold standard
as it can detect any mutation in the EGFR [34]. As with
K-ras testing the sensitivity and speciﬁcity of the test may
be aﬀected by tissue handling and ﬁxation issues. Macro-
or micro-dissection of a tumour block may help to increase
the chance of successfully detecting a mutation as generally a
biopsy needs to contain at least 20% tumour cells to provide
a reliable sequencing result [33].
Currently available testing facilities for direct sequencing
are limited. For example, only 5 laboratories in Australia
performthetestasof2010withnoexternalqualityassurance
program. This makes equitable access to routine testing of
mutation status diﬃcult.
3.4. How to Interpret the Result of Testing? There is strong
evidenceforconsideringEGFRmutationasagoodpredictive
marker for response to an EGFR TKI and it is appropriate
for these patients to receive treatment with an EGFR TKI
for the treatment of metastatic disease [32]. Ideally this
would be given as ﬁrst-line treatment if accessing a test result
in a timely fashion and funded treatment were available.
However, it appears that as long as patients with EGFR
mutations receive an EGFR TKI at some stage in their
treatment, either before or after chemotherapy that overall
survival is similar. However, as it is known that a signiﬁcant
percentage of patients are too unwell to consider second
line therapy, then ﬁrst-line treatment with an EGFR TKI is
preferable. This is also the case for more frail patients who
may not be able to tolerate chemotherapy treatment but
could beneﬁt signiﬁcantly from an EGFR TKI.
Ninety percent of sensitizing mutations involve codon
19 (in-frame deletion or insertion mutations) or codon 21
(L858R missense mutation). Other mutations in the EGFR
may be associated with treatment resistance or are of uncer-
tain signiﬁcance (neutral), for example, exon 18 deletion.
Secondary mutations in the EGFR such as T790M are
describedtobeassociatedwithresistancetoEGFRTKIs[44].
It is important that the treating oncologist takes note of the
exact type of EGFR mutation identiﬁed and ensures that it is
the one described to be associated with response to an EGFR
TKI before starting therapy.
Alternatively, not every patient requires an EGFR muta-
tiontogetbeneﬁtfromanEGFRTKI.Asdescribedabovethe
BR21 study determined that Erlotinib can be of beneﬁt for
the treatment of relapsed disease after prior platinum-based
chemotherapyin NSCLCpatients regardlessof mutation sta-
tus. Also according to the result of SATURN study, Erlotinib
can be given as maintenance treatment after 1st-line chem-
otherapy without knowledge of the EGFR mutation status
and can still confer a small survival beneﬁt [45]. However,
analysis of the subset of patients in the trial who had tissue
available for testing suggests that the beneﬁt was primarily
driven by those who did have EGFR mutant tumours.
3.5.IsTestingSuﬃcienttoPredictResponse? Not every patient
with EGFR mutant NSCLC will respond to an EGFR TKI.
Similar to the story of EGFR monoclonal antibodies in colon
cancer treatment, K-ras mutation can nullify the eﬀect of a
TKI. It has been debated if EGFR and K-ras mutations are
mutually exclusive. But there are deﬁnite reports of cases
with coexistence of the both mutations. However, in general
patients with K-ras mutations will not respond to an EGFR
TKI. PTEN loss or AKT activation by other mechanisms may
also confer resistance to an EGFR TKI [46].
3.6. Is the Testing Cost-Eﬀective? The cost-eﬀectiveness of
EGFR mutation testing speciﬁcally has not been prospec-
tively assessed within all of the pivotal clinical trials per-
formed so far. Economic analysis of the BR21 trial suggested6 Chemotherapy Research and Practice
that with an incremental cost-eﬀectiveness ration of $94,638
per life year gained, Erlotinib treatment for patients with
previously treated advanced NSCLC is marginally cost-
eﬀective in an unselected patient population. The authors
suggest that the use of molecular predictors of beneﬁt for
targeted agents could help to identify more or less cost-
effective subgroups for treatment [47].
The cost-eﬀectiveness of ﬁrst-line treatment is still being
evaluated. A recent assessment by an evidence review group
for the National Institute of Health and Clinical Excellence
(NICE)suggestedthatﬁrst-linetreatmentwithGeﬁtinibmay
not be cost-eﬀective at what would usually be considered
standard levels of willingness to pay for an additional QALY,
largelybecauseofthecostofthedrugtreatment[48].Ofnote
the proposed cost of the test in Australia is only AUD $400–
606. However, recent modelling from a Singapore group
suggested that EGFR testing and ﬁrst-line treatment with
Geﬁtinib would be cost-eﬀective compared to standard care,
primarily because of the cost saving associated with not
providingthedrugtothosewhoarenotlikelytobeneﬁt[49].
4. Conclusion
As we enter a new era of improved survival rates following a
diagnosis of cancer, it is anticipated that targeted therapies
will play an increasing role in treatment strategies. It is
important that the development of predictive molecular
testingoftumoursoccursinparallelwiththedevelopmentof
thesenewtherapiesinordertohelpselectthebesttreatments
for patients. In order for this to successfully occur it is
necessary to have access to good quality tumour tissue for
testing that can occur in a timely fashion, even if this needed
some time after the tissue is acquired.
It is crucial that we have enough numbers of appropriate
staﬀed laboratories to provide high-quality services for
molecular tumour testing. It is also important that there is
a framework to ensure quality control. The testing facilities
need to be suitably resourced to be able keep pace with the
new exciting tumour targets and treatments that are being
discovered and shown to be promising in clinical trials, such
as the recently developed tyrosine kinase inhibitors for
BRAF mutations in melanoma and EML4-ALK mutations in
NSCLC.
In addition, future clinical trials of targeted therapies
need to be designed not only to assess the eﬃcacy and cost-
eﬀectiveness of promising new drugs but also to assess the
associated codiagnostic technologies in order to allow assess-
ment by funding agencies and early integration in clinical
practice. Education of the oncology workforce about the
eﬀective use of codiagnostics in patient management is also
essential.
All of these requirements need to have a backing from
policy makers and government funding bodies. Codepen-
dent technologies need to be able to be assessed by a trans-
parent process simultaneously with new therapies to ensure
rapid approval of both technologies and thus provide indi-
vidualised and quality use of medicines for people aﬀected
by cancer.
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